Partnership for Part D Access
  • Home
  • About Us
    • Who We Are
    • Patient Communities
    • Our Leadership
  • The Issue
    • Six Protected Classes
    • History
  • Resources
  • Newsroom
  • Stakeholder Voices
  • Contact Us
  • Home
  • About Us
    • Who We Are
    • Patient Communities
    • Our Leadership
  • The Issue
    • Six Protected Classes
    • History
  • Resources
  • Newsroom
  • Stakeholder Voices
  • Contact Us

Newsroom​ 

New Research Undermines Insurance Industry Attacks on Medicare's Six Protected Classes

1/29/2020

0 Comments

 
Picture
A pair of recent analyses offer new evidence that Medicare’s protected classes policy does not drive higher costs for the program and beneficiaries, despite attacks from insurance companies who have argued they should be allowed to restrict access to these needed medications. Specifically, the two analyses -- one undertaken by Milliman and the other by BluePeak Advisors -- show that the six protected classes have similar cost patterns to non-protected drugs. 

Among the highlights of the respective analyses: 

  • Milliman Analysis — An analysis from Milliman shows that from 2015-2018, both unprotected and protected class drug costs declined by an average of half a percent annually. This study focuses on drugs’ wholesale acquisition cost (WAC), meaning that notwithstanding formulary tiering by plans, beneficiary cost sharing as well as overall cost is likely to have been stable. While brand drug prices increased over that time, the study says, lower-cost drugs entered the market and achieved utilization rates that kept costs stable. Milliman used its proprietary Part D Consolidated Database (PDCD) for the analysis. The similarity in cost trends between protected and non-protected drugs shows that the protected class designation does not meaningfully influence drug costs and that plans and PBMs are equipped to manage costs, just as they are with non-protected class drugs.

  • BluePeak Consulting Analysis — BluePeak Consulting and ACADIA analyzed CMS’ 2013-2017 actual Medicare expenditure data and broke down costs by drug class. Their results mirrored Milliman’s, but BluePeak also found that costs three of the six protected classes — antidepressants, antipsychotics, and immunosuppressants --declined between 2013 and 2017. The costs of protected class drugs have decreased as much as 14.6 percent on an annualized basis for antidepressants. Antiretrovirals’ costs are growing at roughly the same rate (2.9 percent annually) as all non-protected classes (2.8 percent). Annual cost growth for just two of the six protected classes exceeded non-protected classes as a whole over that five-year period.

These analyses are consistent with a recent study from Avalere, further refuting statements from plans and pharmacy benefit managers (PBM) that they cannot manage utilization of protected class drugs. In fact, the analyses show that drug costs have remained stable in the protected classes and generic utilization has increased – meaning plans are holding costs down as the protected class ensures that individuals with difficult-to-manage conditions are able to get the medication they need.  

0 Comments

Study Finds CMS' Nixed Change to Part D Could Have Hindered Drug Accessibility

7/17/2019

0 Comments

 
Picture
This post originally appeared in Fierce Healthcare on July 16, 2019. 

A new study found a Trump administration proposal to rein in prices on certain drugs under Medicare Part D would have made drugs less accessible to patients. The study, published Tuesday in the Journal of the American Medical Association, explored price hikes over a five-year span for products in protected classes. Medicare Part D requires plans to add to their formularies products in six classes that include antidepressants, antipsychotics and immunosuppressants.


Read More
0 Comments

Trump Administration Backs Off a Proposal to Let Medicare Plans Exclude Certain Drugs

5/17/2019

0 Comments

 
Picture
This post originally appeared in STAT News on May 16, 2019 

WASHINGTON — The Trump administration is backing off a controversial proposal to chip away at existing safeguards that require Medicare to cover all drugs for conditions like depression and AIDS. The initial proposal, which would have allowed private Medicare plans to refuse to pay for certain drugs for chronic conditions that spiked in price, was met with widespread criticism almost as soon as it was proposed last November. The Trump administration had suggested the change would help lower drug prices by giving private Medicare plans more leverage over high-cost drugs. But patient advocates and drug makers said it would jeopardize patient care in life-threatening situations.


Read More
0 Comments

CMS Again Scraps Proposal To Weaken Protected Drug Classes

5/17/2019

0 Comments

 
Picture
This post originally appeared in Inside Health Policy on May 16, 2019. 

Two consecutive administrations have failed to follow through with proposals to weaken Medicare Part D coverage protections in six drug classes. CMS again scrapped the idea in a final Part D rule it issued Thursday (May 16). When it proposed the rule last November, the agency had called for letting Part D plans exclude drugs in protected classes from formularies when their makers raise prices faster than inflation or when drug companies make new formulations of drugs already on the market. The proposed rule also called for allowing Part D plans to more broadly use step therapy and prior authorization for protected class drugs.


Read More
0 Comments

Patient Groups Cheer CMS Retreat on Protected Class Changes

5/17/2019

0 Comments

 
Picture
This post originally appeared in POLITICO on May 17, 2019. 

Assorted health care interests expressed relief Thursday following CMS' decision not to move forward with changes that would have let Medicare Part D and Medicare Advantage plans limit coverage of drugs in six categories known as “protected classes.” Some of the interests even expressed optimism policymakers won’t try to change the benefit again now that both Donald Trump and Barack Obama each failed to generate the needed political support for modification. Under the status quo, Part D plans must cover all drugs in the six protected classes: antidepressants, anti-psychotics, anticonvulsants, immunosupressants for transplant rejection, antiretrovirals and cancer drugs.


Read More
0 Comments

Patient Advocates Commend CMS for Maintaining Medicare’s Six Protected Classes Policy

5/16/2019

1 Comment

 
As designed by Congress, Medicare’s six protected classes policy guarantees access to treatments for Medicare patients with the most complex conditions, including cancer, HIV/AIDS, mental health conditions, epilepsy, organ transplants, and Parkinson’s
Picture
​Washington D.C. — The Partnership for Part D Access, a broad-based coalition of health care stakeholders including over 20 diverse patient advocacy organizations, commended the Centers for Medicare and Medicaid Services (CMS) for not finalizing a proposal that would have substantially weakened Medicare’s six protected classes policy. 


Read More
1 Comment

CMS Removes Protected Classes Changes in Part D Final Rule

5/16/2019

0 Comments

 
Picture
The Centers for Medicare and Medicaid Services (CMS) issued a final rule that makes no changes to the current six protected classes policy — completely eliminating the potentially damaging changes included in a proposed rule released several months earlier. Instead, the agency finalized current practices that allow for prior authorization (PA) and step therapy (ST) to only be used within the protected classes for new starts.  Also consistent with current practice, antiretrovirals remain excluded from utilization management altogether. Importantly, CMS did not finalize exceptions for new formulations of existing drugs or drugs whose prices increase above the urban consumer price index (CPI-U). 

“Medicare beneficiaries with the most complex, chronic conditions are breathing a sigh of relief,” Chuck Ingoglia, the Executive Director of the Partnership said in a statement. “This rule cements the protected classes policy as an essential patient safeguard in Medicare’s prescription drug program."

​The Centers for Medicare and Medicaid Services (CMS) issued a final rule that makes no changes to the current six protected classes policy — completely eliminating the potentially damaging changes included in a proposed rule released several months earlier. Instead, the agency finalized current practices that allow for prior authorization (PA) and step therapy (ST) to only be used within the protected classes for new starts.  Also consistent with current practice, antiretrovirals remain excluded from utilization management altogether. Importantly, CMS did not finalize exceptions for new formulations of existing drugs or drugs whose prices increase above the urban consumer price index (CPI-U). 

“Medicare beneficiaries with the most complex, chronic conditions are breathing a sigh of relief,” Chuck Ingoglia, the Executive Director of the Partnership said in a statement. “This rule cements the protected classes policy as an essential patient safeguard in Medicare’s prescription drug program."

0 Comments

Partnership Applauds House Appropriations Committee for Report Expressing Concerns on ‘Six Protected Classes’

5/7/2019

0 Comments

 
Picture
FOR IMMEDIATE RELEASE
May 7, 2019 
Contact: Shea McCarthy 
smccarthy@thornrun.com 
(202) 285-3866

Washington D.C. — The Partnership for Part D Access, a broad-based coalition of health care stakeholders including over 20 diverse patient advocacy organizations, applauded the House Appropriations Committee for their report on the fiscal year (FY) 2020 Labor-HHS-Education spending measure, which raises concerns with a proposal from the Centers for Medicare and Medicaid Services (CMS) to weaken Medicare’s six protected classes policy. 

Read More
0 Comments

Over 220 HIV Providers Urge Trump Administration to Withdraw Six Protected Classes Changes

4/24/2019

0 Comments

 
Picture
Over 220 HIV providers across the country signed onto a letter from the American Academy of HIV Medicine (AAHIVM) urging the Trump administration to abandon its proposed rule that would weaken Medicare Part D's six protected classes policy. AAHIVM points out that the proposed changes could lead to increased utilization management, resulting in decreased access to lifesaving treatments for Medicare’s most vulnerable beneficiaries. “In HIV, delaying and in some cases blocking patients’ access to tailored treatment is deleterious to not only the patients’ individual health, but also to the broader public health in terms of transmissibility of the virus,” the letter states. “For these reasons, we strongly oppose the Administration’s proposal to weaken the protected classes policy and urge this proposal to be withdrawn.”

​The letter in its entirety can be read here. 

0 Comments

Fact Sheet: Response to CMS' Letters to Congress

4/17/2019

0 Comments

 
Picture
Recently, Centers for Medicare and Medicaid Services (CMS) Administrator Seema Verma sent a letter to several Members of Congress in response to their concerns about proposed changes to Medicare’s six protected classes. This fact sheet includes key substantive excerpts, each of which are followed by important facts and policy details that policymakers should be aware of. ​

0 Comments
<<Previous
Forward>>

    Author

    Write something about yourself. No need to be fancy, just an overview.

    Archives

    November 2021
    March 2021
    February 2021
    January 2021
    November 2020
    January 2020
    July 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    April 2018
    March 2018
    September 2017
    May 2017
    April 2017
    November 2016
    July 2016

    Categories

    All

    RSS Feed

Learn more

About Us
Patient Communities
​Issues
​Background

What's New?

​Newsroom
Resources
​

Contact

Contact Us
E-Mail 
© COPYRIGHT 2018. ALL RIGHTS RESERVED.